1. Introduction {#sec1}
===============

Septic shock is a leading cause of morbidity and mortality among critically ill patients. Despite the use of potent antibiotics and improved intensive care, mortality rates of patients with severe sepsis and septic shock remain high (20--50%) \[[@B1]--[@B3]\]. A better understanding of the underlying mechanisms is important to develop future platforms of effective therapies.

Multiple mechanisms are likely involved in the development of septic shock. Host responses may initially respond to an infection but become amplified and dysregulated, resulting in hemodynamic collapse \[[@B4]\]. Decades of basic science and clinical research indicate that complement factors are involved in septic shock. While complement is an important defense system against bacterial infection, earlier clinical observations suggest that activation of complement factors is associated with detrimental effects in septic shock, such as multiorgan damages and poor outcome \[[@B5]--[@B8]\].

There are three pathways in the complement system: classical, alternative, and lectin. Different initiators activate each pathway but all converge to complement protein C3 and are followed by a common cascade (C5-9), resulting in the deposition of a membrane-attack-complex on targets and the release of chemoattractants (C3a and C5a) for inflammatory cells.

2. Pathophysiology of Complement Involvement in Septic Shock {#sec2}
============================================================

2.1. Involvement of Complement Common Cascade in Septic Shock {#sec2.1}
-------------------------------------------------------------

A series of observations on C3 activation in septic shock patients were reported by a group of Dutch investigators led by Hack and Groeneveld. Activated C3 fragments, C3a and C3b/c, were elevated in septic shock patients and correlated with mortality \[[@B9]--[@B13]\]. Other clinical investigators also reported similar findings. Dofferhoff et al. found that, in 20 sepsis patients, C3a and C3d were elevated and that C3a levels correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores \[[@B14]\]. Furebring et al. showed that, in 12 patients with severe sepsis or septic shock, C3a (as well as C5b-9) levels were increased at the time of diagnosis \[[@B15]\]. These clinical observations suggest that C3 fragments released during septic shock may contribute to the development of fatal complications like profound hypotension and disseminated intravascular coagulation (DIC), thereby leading to a more severe disease course and a poor outcome.

It is interesting to note that some investigations did not conclude that C3 activation was detrimental in the development of severe sepsis. For instance, Shatney and Benner reported that in traumatic patients with acute systemic sepsis, serum C3 levels decreased shortly after admission \[[@B16]\]. Thereafter, C3 levels gradually returned to normal, despite the onset of fulminant systemic sepsis. These investigators argued that changes in C3 levels during severe sepsis were more consistent with protective host defense functions but did not support a role for C3 in the pathogenesis of acute fulminant clinical sepsis.

Basic science researchers have used various animal models to investigate the role of complement factors (mostly C3 and C5) in the common cascade. In a study using *E. coli* to induce septic shock in anaesthetized and artificially ventilated rabbits, circulating C5a positively correlated with endotoxin and the degree of accumulation of granulocytes in the lung tissue \[[@B17]\]. Using a baboon model with *E. coli*-induced septic shock, high amounts of endotoxin led to uncontrolled activation of complement C3 and C5-9 \[[@B18]\]. In a pig model of sepsis induced by fecal peritonitis, terminal complement complexeswere found to have been deposited in the kidneys \[[@B19]\].

The availabilities of several strains of complement factor knockout mice have greatly facilitated septic shock research, but conflicting results have been reported depending on the model that investigators chose. Yeh\'s group in Canada reported that like mice incapable of C3a/C3a receptor signaling, C5a receptor C5l2-deficient mice were hypersensitive to lipopolysaccharide- (LPS-) induced septic shock \[[@B20]\]. However, Ward\'s group in USA reported opposite findings using a mouse model of cecal ligation and puncture (CLP), which induces polymicrobial sepsis.In "mid-grade" sepsis (30--40% survival), blockade or absence of either C5a receptors, C5ar or C5l2, greatly improved survival and attenuated the buildup of proinflammatory mediators in plasma \[[@B21]\]. In "high-grade" sepsis (100% fatality), the only protective condition was the combined blockade of C5l2 and C5ar.Ward\'s group further showed that C5a induces apoptosis in adrenomedullary cells during experimental sepsis \[[@B22]\].

C3^−/−^ mice had significantly reduced survival in 2 septic shock models (LPS-induced and CLP) \[[@B23], [@B24]\]. Surprisingly, C5^−/−^ mice showed identical survival as wild type controls in CLP model \[[@B24]\]. In addition, C6-deficient rats had no significant differences in lung inflammation in an LPS-induced septic shock model \[[@B25]\].

These data suggest that C3 is essential to control bacteremia in 2 different models, but the functions of C5-9 seem dispensable. Depending on the type of animal model, anaphylatoxins C3a and C5a may be important factors in recruitment of inflammatory cells to combat infections but excessive release of these factors could be detrimental.

2.2. Involvement of Complement Classical Pathway in Septic Shock {#sec2.2}
----------------------------------------------------------------

Specific factors in complement classical pathway include immunoglobulins, C4 and C2. Animal studies showed that C3^−/−^, C4^−/−^, Btk^−/−^ (immunoglobulin deficient) and RAG-2^−/−^ (immunoglobulin deficient) mice were significantly more sensitive to endotoxin than wild-type controls \[[@B23], [@B26]\], suggesting an essential role for complement classical pathway to clear endotoxins.

Clinical investigators have explored the involvement of classical pathway in septic shock since the early 1980s. In a clinical study of 48 patients (19 with septic shock), those with septic shock had markedly decreased levels of C3, C4, and total complement activity as measured by the 50% hemolytic complement (CH~50~) assay. However, after 96 h, these values returned to baseline \[[@B27]\]. This underlines the transitory activation of the complement system through the classic pathway in septic shock. C4 activation, manifested as decrease of C4 or increase of C4a, was also reported in other clinical studies of severe late septic shock (42 patients) \[[@B28]\], clinically suspected sepsis on admission (43 of 47 patients) \[[@B13]\], severe sepsis and septic shock (50 patients) \[[@B29], [@B30]\]. IgG has also been associated with clinical outcomes of septic shock. In a study of 50 patients with severe sepsis or septic shock, survivors showed significantly higher levels of IgG upon diagnosis than those who ultimately died \[[@B30]\]. Thus, complement classical pathway is activated in septic shock as an essential response to clear endotoxins.

2.3. Involvement of Complement Alternative Pathway in Septic Shock {#sec2.3}
------------------------------------------------------------------

Specific factors in complement alternative pathway include factors B and D, which are regulated by factors H, I, and P (also called properdin). The alternative pathway is a critical defense system against bacterial infection. Patients with preexisting deficiency in factors of alternative pathway, for example, factor D and properdin, could suffer fulminant meningococcal infections resulting in septic shock \[[@B31]--[@B33]\].

Evidence of activation of alternative pathway in septic shock has been reported in a number of clinical studies. A study of 42 patients with severe late septic shock found factor B levels were significantly lower in patients who died than in patients who survived \[[@B28]\]. In these patients, the alternative pathway appears to be activated early in septic shock, whereas the classical pathway is activated later. Oglesby et al. also reported that among septic shock patients (both Gram-negative and Gram-positive) with preexisting cirrhosis, factor B levels were decreased \[[@B34]\]. Lin et al. reported that the active fragment of factor B, Bb as well as the Bb to factor B ratio, was significantly increased in septic shock patients \[[@B29]\]. Brandtzaeg et al. showed that among 20 patients with systemic meningococcal disease, ten patients with persistent septic shock had significantly higher levels of Bb than the other 10 patients without septic shock \[[@B35]\]. Finally, PBMCs from septic shock patients showed increased factor B mRNA expression when compared with control patients \[[@B36]\]. All these evidences suggest that complement alternative pathway is essential to fight against infections and is activated in clinical settings of septic shock.

2.4. Involvement of Complement Lectin Pathway in Septic Shock {#sec2.4}
-------------------------------------------------------------

Specific factors in complement lectin pathway include MBL and ficolin. Both MBL and ficolin circulate in complexes with one of three MBL-associated serine proteases (MASPs) \[[@B37], [@B38]\], with MASP-2 being the major complement-activating component among the three known MASPs. The MASP-2 is activated when MBL binds to certain carbohydrate or acetyl patterns on pathogens \[[@B39]--[@B41]\]. The activated MASP-2 then cleaves C4 and C2 to form the C3 convertase, C4b2a. MASP-2 activation is regulated by C1-inhibitor \[[@B42]--[@B44]\].

Basic research has shown that MBL and MASPs can bind to certain LPS containing a mannose homopolysaccharide. Such a binding of LPS to MBL and MASPs may cause C4 activation, resulting in the platelet response and development of rapid shock in mice \[[@B45]\].

However, two clinical studies from Eisen\'s group in Australia showed more complicated patterns of lectin complement activation in septic shock. In a study of 128 patients with sepsis and septic shock, the majority of patients did not display an MBL acute phase response on days 1, 3, 5, 7 \[[@B46]\]. Forty percent of these patients maintained consistent MBL levels throughout hospital stay, thirty percent of these patients had a positive acute phase response, and the remaining had a negative acute phase response \[[@B46]\]. In another study of 114 septic shock patients and 81 sepsis patients, MBL functional deficient patients had significantly higher sequential organ failure assessment (SOFA) scores, while higher MBL function and levels were found in patients who had SOFA scores predictive of good outcomes \[[@B47]\]. Thus, Eisen\'s group suggested that deficiency of MBL function may be associated with bloodstream infection and the development of septic shock.

Even with a likely protective role of MBL against sepsis, it is still possible that excessive activation of lectin pathway may contribute to the detrimental effects in septic shock. Sprong et al. reported two cases of MBL-deficient septic shock patients who had relatively low disease severity and mild disseminated intravascular coagulation (DIC) compared with 16 septic shock patients who had sufficient levels of MBL \[[@B48]\].

It is still unclear whether other molecules in the lectin pathway are involved in septic shock. We have investigated the temporal patterns of MASP-2 in 16 septic shock patients and their correlation with in-hospital mortality. Our preliminary results showed that there was no difference in the baseline levels of MASP-2 between survivors and nonsurvivors. However, there was a trend that survivors had an increase of MASP-2 over the course of 5 days, while the nonsurvivors had a decrease during the same time period (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). The change of MASP-2 in survivors at 6 hours after diagnosis of septic shock was significantly different than that of nonsurvivors ([Figure 1(c)](#fig1){ref-type="fig"}). Kaplan-Meier survival analysis showed that patients with ≥10% increase of MASP-2 within 6 hours after the diagnosis of septic shock had significantly less in-hospital mortality than patients with ≥10% decrease of MASP-2 during the same time period ([Figure 1(d)](#fig1){ref-type="fig"}). Therefore, acute decrease of MASP-2 during the early phase of septic shock may correlate with in-hospital mortality.

It remains to be determined to what degree is lectin complement activation necessary for protective effect against infection and whether there is threshold for the activation before detrimental effects appear. Future research, especially laboratory studies, may answer these questions.

2.5. Involvement of Other Complement-Related Inflammatory Mediators in Septic Shock {#sec2.5}
-----------------------------------------------------------------------------------

The development of septic shock is multifactorial and many potential mechanisms have been reviewed extensively by others \[[@B49]--[@B52]\]. Thus, this paper will only briefly describe the potential links between the complement system and its related inflammatory mediators in septic shock.

Septic patients often exhibit a relative deficiency of C1-inhibitor (C1-INH) \[[@B53]\], which can inhibit activation of all 3 complement pathways \[[@B54]--[@B56]\]. C1-INH also inhibits proteases of the fibrinolytic, clotting, and kinin pathways. It is likely that during septic shock C1-INH may be depleted from the circulation by binding to factors in coagulation/fibrinolysis \[[@B57]\], thereby unable to control the excessive complement activation.

Cytokines and chemokines, particularly TNF-*α* and IL-6, are considered the first line biomarkers that drive the dynamic process of sepsis \[[@B58]\]. Cytokines and complement components can be activated similarly in sepsis \[[@B11], [@B14], [@B59]--[@B62]\] and their activation products may have overlapping biological activities \[[@B63]\]. Therefore, concomitant activation of cytokines and complements may amplify systemic inflammation leading to organ and system failure.

Other circulating inflammatory mediators, including plasma prostaglandin (PGI) and phospholipase A-2 (PLA-2), may be activated in parallel with complements in septic shock and have direct association with complement factors \[[@B64], [@B65]\]. Thus, like cytokines, these mediators may have synergistic effects with complements in the development of septic shock.

3. Complement-Related Therapeutic Strategies for Septic Shock {#sec3}
=============================================================

Current management of septic shock includes early identification andtreatmentof the causative infection \[[@B66]--[@B68]\], adequate and rapid hemodynamic resuscitation \[[@B52], [@B69a], [@B69b]\], treatment of organ failure, corticosteroids \[[@B71]\], and modulation of the immune response \[[@B72], [@B73]\]. There are many comprehensive reviews on these topics and hence we will only review those strategies related to complements.

3.1. Strategies Directly Targeting Complement System {#sec3.1}
----------------------------------------------------

### 3.1.1. Anti-C5a Treatment to Block Neutrophil Chemotaxis {#sec3.1.1}

Given the potential role of C5a in the development of septic shock, anti-C5a agents or C5a receptors-blockers may be reasonable therapeutic approaches. One benefit of C5a-blockade is that it still allows for terminal complement complex formation which is important to fight against infection. Anti-C5a has been tested in several septic shock models. In a primate model, anti-C5a antibody treatment significantly attenuated septic shock and pulmonary edema \[[@B74]\]. In a rat model of LPS-induced septic shock, pretreatment with F(ab′)2 fragments of rabbit anti-rat C5a did not change the circulating cell counts compared with LPS alone; however, a significant improvement in the mean arterial pressure and a decrease in hematocrit were observed \[[@B75]\]. In a pig model, pretreatment with anti-C5a mAb resulted in a decrease of serum IL-6 activity compared to control animals \[[@B76]\]. In a rodent model, blockade of C5a using neutralizing antibodies dramatically improved survival, reduced apoptosis of lymphoid cells, and attenuated the ensuing coagulopathy \[[@B77]\].

These anti-C5a approaches were based on the hypothesis (with supporting evidence) that C5a induced-neutrophil chemotaxis is harmful in septic shock. However, the effectiveness of anti-C5a in clinical settings remains to be tested. Even though it may have some beneficial effects, it may not be the ultimate solution for severe sepsis/shock, particularly because the role of neutrophils in sepsis may change at different stages of sepsis and inhibition of neutrophil chemotactic response could be detrimental in severe sepsis \[[@B78], [@B79]\].

### 3.1.2. C1-INH {#sec3.1.2}

Administration of C1-INH can block complement activation, and its beneficial effect, although modest, in severe sepsis or septic shock has been demonstrated in animal studies \[[@B80], [@B81]\]. C1-INH has been tested in small clinical trials. In a trial of 7 patients with streptococcal toxic shock syndrome, administration of C1-INH markedly shifted fluid from extravascular to intravascular compartments, and 6 of these 7 patients survived \[[@B82]\]. In another trial of 40 patients with severe sepsis or septic shock, C1-INH treatment had a beneficial, although mild, effect on organ dysfunction \[[@B83]\]. These modest effects of C1-INH in septic shock are likely due to nonspecific inhibition of all 3 complement pathways. In another word, it not only suppresses complement-related systemic inflammation, but also hampers complement related antimicrobial responses.

3.2. Strategies Indirectly Affecting Complement System {#sec3.2}
------------------------------------------------------

Anti-TNF treatment (using humanized antibody to neutralize TNF-*α*) has been tested in a number of clinical trials of septic shock, and this topic has been thoroughly reviewed by others recently \[[@B84]\]. In short, although there was a trend of beneficial effect for anti-TNF to reduce sepsis-associated risk of death, none of these trials showed significance. One interesting notion is that inhibition of TNF alone does not reduce complement activation during sepsis, as demonstrated in a baboon model \[[@B85]\]. Thus, it is possible that inhibiting TNF without tackling excessive complement activation only provides a partial protection against systemic inflammation in septic shock. Combination of both anti-TNF and blockage of complement activation may lead to more effective protection.

Extracorporeal immunoadsorption (ECIA) using polymyxin B-immobilized fiber column hemoperfusion has been tested in animal models \[[@B86]\] and clinical trials \[[@B68], [@B87], [@B88]\]. ECIA has been used to adsorb endotoxin, monocytes, activated neutrophils, and anandamide \[[@B88]\], which may indirectly decrease complement activation \[[@B89], [@B90]\].

4. Conclusion {#sec4}
=============

Complement system is essential to combat infections. However, it is a double-edged sword as excessive activation may cause severe injury to the host, as seen in septic shock. Direct or indirect inhibition of complement may provide new approaches in managing septic shock. Future research directions in this area may include (1) clarifying the pattern of complement activation, for example, time course; (2) determining the degree of involvement of three complement pathways in protection and detrimental effects; (3) reconciling the observations in different animal models; (4) further testing of anti-C5a and C1-INH in randomized clinical trials; (5) developing other specific and effective targeting strategies, for example, C3a inhibition.
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![MASP-2 level changes in the survivors or nonsurvivors of septic shock. Plasma levels of MASP-2 were measured over the first 5 days in 16 patients after the diagnosis of septic shock. (a) MASP-2 profiles in the survivors: each line represents an individual patient; (b) MASP-2 profiles in the nonsurvivors; (c) comparison of the change of MASP-2 in survivors versus nonsurvivors at 6 hours after enrollment; (d) the association of changes in plasma levels of MASP-2 at 6 hrs after enrollment with hospital outcome. Kaplan-Meier survival analysis was performed to determine if patients with ≥10% increase of MASP-2 within 6 hours after the diagnosis of septic shock (solid line) had different in-hospital mortality rate compared with patients with ≥10% decrease of MASP-2 over the same time point (dashed line). \*indicates statistical difference (*P* \< 0.05).](CDI2012-407324.001){#fig1}
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